ZAHRANIČNÍ HOSTÉ NA KONFERENCI HEMATOLOGIE 2024
prof Antonio Medina Almeida, MD – EHA President lecture
Instituto Português de Oncologia de Lisboa, Portugal, European Hematology Association President
He currently serves as European Hematology Association president and research interests include pathophysiology and novel treatment targets for myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation.
prof Dr. Med. Andreas Hochhaus – Chronic myeloid leukemia
Director, Department of Hematology and Oncology Director, University Tumor Center Jena, Germany
He is known for his contribution in the field of understanding of chronic myeloid leukemia biology and new thereapeutic approaches.
prof Tomas Ganz, MD – Iron hepcidin
Professor, Medicine, University of California Los Angeles
Professor, Pathology and Laboratory Medicine, University of California Los Angeles
He is known for the ground-breaking research in iron homeostasis, including the discovery of the iron-regulatory hormone hepcidin and investigation of its roles in iron metabolism. He is focused on hemochromatosis, erythroferrone hormone, anemia, innate immunity and inflammation.
prof Olivier Hermine, MD, PhD – Rare diseases
Head of the Hematology and Immunology Department at Hôpital Necker, Assistance Publique-Hôpitaux de Paris in France
He is focused on the characterization of mechanisms governing the physiopathology of hematological disorders including rare diseases and the development of therapeutic strategies for them.
Mazyar Shadman, MD, M.P.H – Chronic lymphocytic leukemia
Innovators Network Endowed Chair
Associate Professor of Hematology and Oncology Lymphoid Malignancies and Immunotherapy Fred Hutch Cancer Centre and University of Washington Seattle, WA
He is involved in clinical research using novel therapeutic agents as well as immunotherapy (specifically CAR T cell therapy) for lymphoid neoplasms.
Dr. Liran Shlush – Clonal haematopoiesis
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
He leads a multidisciplinary lab composed of hematologists, evolutionary biologists and computational system biologists, all trying to understand the rules of human hematopoietic aging and how they are linked to the disease evolution.